4//SEC Filing
Guyer William 4
Accession 0001193125-25-272572
CIK 0001088856other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 5:10 PM ET
Size
11.8 KB
Accession
0001193125-25-272572
Insider Transaction Report
Form 4
Guyer William
Chief Development Officer
Transactions
- Sale
Common Stock
2025-11-05$74.75/sh−6,536$488,559→ 18,751 total - Sale
Common Stock
2025-11-05$76.28/sh−300$22,884→ 5,287 total - Exercise/Conversion
Stock option (right to buy)
2025-11-05−20,000→ 290,000 totalExercise: $21.65Exp: 2031-09-01→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2025-11-05$21.65/sh+20,000$433,000→ 25,287 total - Sale
Common Stock
2025-11-05$75.64/sh−13,164$995,679→ 5,587 total
Footnotes (4)
- [F1]The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
- [F2]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.17 to $75.165 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F3]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $75.185 to $76.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F4]Fully exercisable.
Documents
Issuer
CORCEPT THERAPEUTICS INC
CIK 0001088856
Entity typeother
Related Parties
1- filerCIK 0001879013
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 5:10 PM ET
- Size
- 11.8 KB